Non-Cystic Fibrosis Bronchiectasis (NCFB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
-1.jpg)
Non-cystic fibrosis bronchiectasis (NCFB) is an incurable pulmonary disorder characterized pathologically by permanent bronchial dilatation and severe bronchial inflammation and clinically by chronic productive cough and recurrent infectious exacerbations. It is further characterized by permanent dilatation of the airways leading to persistent cough, sputum production, dyspnoea, and recurrent exacerbations. Current clinical management is typically multifaceted and includes treatment of concurrent etiologic conditions, promotion of airway clearance, reduction in bronchial inflammation, and suppression or prevention of chronic bronchial infection.
·
In the USA, the incidence of cases of
Non-cystic fibrosis bronchiectasis (NCFB) ranges from 33 to 79 cases for a
100,000 population. The prevalence cases range between 142 to 221 cases per
100,000 persons.
·
Women are more susceptible to this disease;
the number of women is almost double compared to men.
Thelansis’s “Non-Cystic Fibrosis
Bronchiectasis (NCFB) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Non-Cystic
Fibrosis Bronchiectasis (NCFB) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Non-Cystic Fibrosis Bronchiectasis (NCFB) across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Non-Cystic Fibrosis Bronchiectasis
(NCFB) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment